Navigation Links
Chimerix To Present At Therapeutic Area Partnerships Meeting
Date:11/26/2012

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that President and Chief Executive Officer Kenneth I. Moch will present at the 2012 Therapeutic Area Partnerships meeting in Boston, MA.  His presentation will include an update on the company's clinical pipeline, including its lead development compound, CMX001, which was named by conference organizers a "Top 10 Project to Watch in Infectious Diseases." 

Mr. Moch will be presenting on Thursday, November 29 at 3:50 p.m. EST at the Westin Copley Place during the Infectious Diseases Projects to Watch session.  Therapeutic Area Partnerships is regarded as one of the industry's premier biopharmaceutical partnering event.  More information can be found on the meeting's web site:  www.tapartnerships.com.  

About Chimerix
Chimerix is developing novel oral antiviral therapeutics with the potential to improve outcomes for patients in multiple therapeutic areas, including transplant, oncology, acute care and global health. The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates that have demonstrated the potential for enhanced activity and safety compared with currently approved drugs.

Chimerix's lead clinical-stage drug candidate, CMX001, is a novel, broad-spectrum, oral antiviral that inhibits double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus. CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV in hematopoietic stem cell transplant (HSCT) recipients and is in Phase 2 development for the preemption and treatment of AdV infection. To date, more than 800 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
2. Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
6. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
7. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
8. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
9. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
10. PRA Expert to Present at Pharmacovigilance Conference
11. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pittsburgh, PA (PRWEB) July 25, 2014 ... annual Call for Topics for Conferee Networking. These two-hour ... similar interests to meet and resolve problems, discuss new ... , The deadline to submit a topic for consideration ... at pittcon.org . The Conferee Networking committee will ...
(Date:7/25/2014)... BENSALEM, Pa. , July 25, 2014 /PRNewswire-iReach/ ... services and consulting for global corporations operating in ... will host its first annual Global User Group ... in historic Philadelphia, Pennsylvania ... Photo - http://photos.prnewswire.com/prnh/20140724/130263 ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... Calif. , July 24, 2014  Now available ... to home. Rehealth Regenerative Therapies , located in ... and other physically active people a new health option: ... Regardless of age, countless patients suffer from joint ... activities, such as muscle tears, torn rotator cuff, tennis ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... , , Mark Churchill and Mark Harrison, Thermo Finnigan, , ... , , Bioanalytical Method Validation , ... using , a Thermo Finnigan TSQ Quantum mass spectrometer, , ... , , , , Guidelines on Bioanalytical ...
... , , , , , , ... Beecham Pharmaceuticals , , Metabolite ... Finnigan LCQ , Series of ion trap mass spectrometers. , ... , An integral part of the process by ...
... , , , , Jack Cunniff, Philip Tiller, Michael Harvey, ... , , , , , ... using the Thermo Finnigan LCQ , Series of ion trap mass spectrometers. , ... , For more than five thousand years tea has been used in ...
Cached Biology Technology:Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 2Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 3Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 4Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 5Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine , in Bovine Plasma using the TSQ Quantum Mass Spectrometer 6In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 2In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 3In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 4In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 5In-Vitro Metabolism Studies Using Data-Dependent LC/MSn 6Structural Determination of Flavonoids Using MSn 2Structural Determination of Flavonoids Using MSn 3Structural Determination of Flavonoids Using MSn 4
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... what they want, to paraphrase the Rolling Stones, but sometimes ... that will appear in the May issue of the ... broad sweep of evolutionary changes in life on earth as ... shifts. And yet the amount of variability seen among successive ...
... ,PORTLAND, Ore. April 2, 2010. Countless studies and reports exist ... is the impact on the soil? Should one leave the ... offsite in preparation for replanting the area in the future? ... possible, that the debris remaining on the ground after logging ...
... (ACMGF) has awarded Dr. Marilyn M. Li, of the ... Medicine the 2010-2011 Luminex/ACMGF Award at the ACMG 2010 ... includes a $100,000 grant and is aimed at the ... including the development of research guidelines. "Medical ...
Cached Biology News:Ecologists receive mixed news from fossil record 2Study reveals that logging debris suppresses development of an invasive competitor, Scotch broom 2Dr. Marilyn M. Li, M.D., FACMG, is the 2010 Luminex/ACMGF award recipient 2
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Antibeta-lactoglobulin monoclonal antibody(CD-2)...
MAb to Vasopressin Preservative: NaN3...
Biology Products: